Back to search

Article

Exploring Regorafenib Responsiveness and Uncovering Molecular Mechanisms in Recurrent Glioblastoma Tumors Through Longitudinal In Vitro Sampling

2024-02-08

Abstract excerpt

Glioblastoma, a deadly brain tumor, shows limited response to standard therapies like te-mozolomide (TMZ). Recent findings from the REGOMA trial underscore a significant survival improvement offered by regorafenib (REGO) in recurrent glioblastoma. Our study aimed to propose a 3D ex vivo drug response precision medicine approach to investigate recurrent glio-blastoma sensitivity to REGO and elucidate the underlying...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
b2791137-4fde-5581-963f-1655160969ea
DOI
10.20944/preprints202402.0501.v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Exploring Regorafenib Responsiveness and Uncovering Molecular Mechanisms in Recurrent Glioblastoma Tumors Through Longitudinal In Vitro SamplingDOI 10.20944/preprints202402.0501.v1
Metabolic-imaging of human glioblastoma live tumors: a new precision-medicine approach to predict tumor treatment response earlySemantic proximity
NAPH-Fluorescence Lifetime Imaging informed machine learning modelling reliably predicts Temozolomide responsiveness in GlioblastomaSemantic proximity
Clinical and NGS predictors of response to regorafenib in recurrent glioblastomaSemantic proximity
Intratumoral Heterogeneity and Longitudinal Changes in Gene Expression Predict Differential Drug Sensitivity in Newly Diagnosed and Recurrent GlioblastomaSemantic proximity
Gliamimic: A Longitudinal, Multimodal in Vitro Platform for Evaluating Glioblastoma Treatment Response and Relapse in Patient-derived Organoids or SpheroidsSemantic proximity
IDHwt glioblastomas can be stratified by their transcriptional response to standard treatment, with implications for targeted therapySemantic proximity
Single‐cell RNA sequencing reveals tumor heterogeneity, microenvironment, and drug‐resistance mechanisms of recurrent glioblastomaSemantic proximity
Identification of inter- and intra-tumoral molecular phenotypes steering temozolomide resistance in patient-derived glioblastoma cellsSemantic proximity
Systematic in vitro analysis of therapy resistance in glioblastoma cell lines by integration of clonogenic survival data with multi-level molecular dataSemantic proximity
A molecular signature associated with prolonged survival in glioblastoma patients treated with regorafenibSemantic proximity
Characterization of the minimal residual disease state reveals distinct evolutionary trajectories of human glioblastomaSemantic proximity
Targeting Glioblastoma Cell State Plasticity for Enhanced Therapeutic EfficacySemantic proximity
Select a neighboring publication to make it the new centre.